Synergen Inc

Company Information

Company Name
Synergen Inc
Address
1885 33rd St
Boulder, CO, 80301
Phone
n/a
URL
n/a
DUNS
n/a
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$349,092.00
7
SBIR Phase II
$440,212.00
1
Chart code to be here

Award List

  1. ANTIPLAQUE PROTEINS VIA GENETIC ENGINEERING

    Amount: $440,212.00

    SYNERGEN, INC.'S PROPOSED RESEARCH WILL DEVELOP, THROUGH RECOMBINANT DNA METHODS, NEW AGENTS TO CONTROL DENTAL PLAQUETHESE WILL CONSIST OF AN ENZYMATIC MOIETY OF THERAPEUTIC VALUE FUSED WIH AN ADHESIV ...

    SBIR Phase II 1989 Department of Health and Human Services
  2. DEVELOPMENT OF AMIDASES FOR USE IN BETA-LACTAM MODIFICATION

    Amount: $50,000.00

    SEVERAL CLINICALLY IMPORTANT BETA-LACTAM ANTIBIOTICS ARE PRODUCED THROUGH CONDENSATION OF D-(-)-ALPHA-AMINOPHENYLACETIC ACID WITH PENAM AND CEPHEM NUCLEI IN MULTI-STEP CHEMICAL PROCESSES. AN EFFICIENT ...

    SBIR Phase I 1988 Department of Health and Human Services
  3. THERAPEUTIC CLEARANCE OF COMPLEMENT FRAGMENT C5A

    Amount: $50,000.00

    THE OVERALL GOAL OF THE PROPOSED RESEARCH IS TO PROVIDE A SPECIFIC, PRACTICAL MEANS FOR INACTIVATING C5A IN PATIENTS AT RISK OF ADULT RESPIRATORY DISTRESS SYNDROME (ARDS). C5A IS A KEY CONTRIBUTORY, P ...

    SBIR Phase I 1988 Department of Health and Human Services
  4. A HUMAN IL-1 INHIBITOR FOR THE TREATMENT OF SEPTIC SHOCK

    Amount: $49,326.00

    WE PROPOSE TO PURIFY AN IL-1 INHIBITOR FROM THE SUPERNATANT OF MONOCYTES CULTURED ON PLATES COATED WITH IGG. THIS INHIBITORY ACTIVITY HAS BEEN SHOWN TO BE ABOUT 22 KILODALTONS IN MOLECULAR WEIGHT AND ...

    SBIR Phase I 1988 NavyDepartment of Defense
  5. KALLIKREIN INHIBITORS BY GENETIC ENGINEERING

    Amount: $50,000.00

    THE AIM OF THIS RESEARCH IS TO PRODUCE INHIBITORS OF HUMAN KALLIKREINS THAT BLOCK KALLIKREIN-MEDIATED CONVERSION OF KININOGENS INTO KININS. KININS ARE IMPLICATED IN THE SYMPTOMS OF ALLERGIC RHINITIS, ...

    SBIR Phase I 1989 Department of Health and Human Services
  6. NEW DRUG FOR PREVENTING POST-ISCHEMIC TISSUE INJURY

    Amount: $50,000.00

    NEUTROPHILS ARE A MAJOR CONTRIBUTOR TO THE CELLULAR DAMAGE THAT ACCOMPANIES REPERFUSION OF ISCHEMIC TISSUES. IT IS PLANNED TO CLONE AND PRODUCE THROUGH RECOMBINANT DNA METHODS A HUMAN PROTEIN THAT BLO ...

    SBIR Phase I 1989 Department of Health and Human Services
  7. VACCINE AGAINST HAEMOPHILUS INFLUENZAE TYPE B

    Amount: $49,766.00

    THIS RESEARCH WILL LEAD TO THE DEVELOPMENT OF A VACCINE THAT CAN BE USED TO PROTECT YOUNG CHILDREN AGAINST INFECTIONS CAUSED BY HAEMOPHILUS INFLUENZAE TYPE B (HIB). THE VACCINE WILL BE BASED ON THE PI ...

    SBIR Phase I 1989 Department of Health and Human Services
  8. ANTIPLAQUE PROTEINS VIA GENETIC ENGINEERING

    Amount: $50,000.00

    N/A

    SBIR Phase I 1987 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government